Sedana Medical AB (publ) reports record-breaking sales growth in the first quarter of 2018.
Sedana Medical AB ("Sedana Medical or the Company") reports a more than expected 60% increase in sales in the first quarter of 2018 compared to the corresponding period in 2017.
During the initial listing Sedana Medical announced a target to increase sales by 20% per year on average until the registration of the pharmaceutical IsoConDa. For the full year 2017, sales increased by 26% compared with 2016.
Sales during the first quarter of 2018 amounted to TSEK 15,486 (TSEK 9,681), which is an increase of 60% compared to the corresponding period in 2017. This is more than previously expected. Corrected for the strong Euro, the increase is about 50%. Sales in Germany continue to increase sharply and represent 88% of total sales. The main reasons for this increase is that many existing clinics have increased their use of Inhalation Sedation as well as that several new clinics have begun to use the therapy. France has now also started to gain momentum from a low starting point.
For additional information, please contact:
Christer Ahlberg, CEO, Sedana Medical AB
+46 70 675 33 30
Sedana Medical is listed on Nasdaq First North in Stockholm
and Erik Penser Bank (+46 8 463 83 00) is certified adviser to Sedana Medical.
This information is such that Sedana Medical AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on 12 April 2018 at 22.30 PM (CET).
Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients.
Sedana Medical has direct sales in the Nordic countries, Germany, France and Spain as well as external distributors in the rest of Europe, Middle East, Canada, Australia and South Korea. The company headquarters are based in Stockholm, Sweden with R&D operations in Ireland.